Condition: Advanced Malignant Solid Tumor · Sponsor: CAS Lamvac Biotech Co., Ltd.
The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors. 2) To explore the safe and effective course of the Plasmodium immunotherapy for the advanced malignant solid tumors. 3) To explore the possible indications of Plasmodium immunotherapy for advanced malignant solid tumors. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.
This description comes directly from the study's public registry record.
Qin Li, Ph.D · 0086-18802043960 · qin_li@cas-lamvac.com
Huang Qiumei, M.D · 0086-20-82258809 · huang_qiumei@cas-lamvac.com
Always discuss trial participation with your own doctor first.
| Yunnan Kungang Hospital | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04165590